TABLE 1

Baseline characteristics of study participants

CharacteristicaAll (n =105)HIV (n = 62)TB/HIV (n = 43)P value
Median (IQR) age (yrs)7.0 (5.0 to 10.0)8.5 (5.4 to 10.8)6.3 (4.4 to 9.0)0.027
Median (IQR) body wt (kg)17.0 (13.5 to 23.2)20.4 (15.0 to 25.2)15.0 (13.0 to 19.6)0.002
Median (IQR) ht (cm)111.0 (95.0 to 125.0)119.5 (98.0 to 130.0)103.0 (93.0 to 120.0)0.022
Age range (yrs)0.039
    3 to <529 (27.6)13 (21.0)16 (37.2)
    5 to <1040 (38.1)22 (35.5)18 (41.9)
    10 to 1436 (34.3)27 (43.5)9 (20.9)
Sex0.689
    Male60 (57.1)34 (54.8)26 (60.5)
    Female45 (42.9)28 (45.2)17 (39.5)
CYP2B6 516G→T genotype (n = 101)0.492
    GG21 (20.8)12 (20.0)9 (22.0)
    GT54 (53.5)30 (50.0)24 (58.5)
    TT26 (25.7)18 (30.0)8 (19.5)
Nutritional status (median [IQR])
    Weight-for-age Z score (n = 79)–2.3 (–3.0 to –1.1)–1.8 (–2.8 to –0.9)–2.5 (–3.0 to –1.7)0.043
    Height-for-age Z score–2.7 (–3.3 to –2.0)–2.6 (–3.3 to –1.5)–2.8 (–3.6 to –2.2)0.249
    BMI-for-age Z score–0.5 (–1.8 to 0.3)–0.4 (–1.5 to 0.2)–0.7 (–2.2 to 0.5)0.446
Median (IQR) efavirenz dose (mg/kg)15.0 (13.7 to 16.9)14.3 (13.2 to 16.2)15.8 (15.0 to 18.8)<0.001
Laboratory results (median [IQR])
    White blood cell count (×109/liter) (n = 59)6.4 (4.4 to 9.4)6.2 (4.3 to 8.8)7.2 (4.6 to 9.8)0.474
    Absolute neutrophil count (cell/) (n = 50)2.2 (1.4 to 3.1)2.4 (1.6 to 3.1)1.7 (1.3 to 3.1)0.458
    Hemoglobin (g/dl) (n = 59)10.3 (9.3 to 11.1)10.4 (9.6 to 11.1)10.0 (8.9 to 11.1)0.202
    Hematocrit (%) (n = 59)30.3 (28.1 to 33.2)30.3 (28.2 to 33.3)30.4 (27.0 to 33.0)0.365
    Platelets (×109/liter) (n = 58)307.5 (217.0 to 422.0)307.5 (230.0 to 416.0)315.5 (209.5 to 483.0)0.877
    Blood urea nitrogen (mmol/liter) (n = 62)2.6 (1.8 to 3.2)2.7 (1.8 to 3.1)2.5 (1.6 to 3.3)0.578
    Serum creatinine (µmol/liter) (n = 65)35.0 (27.0 to 48.0)34.0 (26.0 to 48.0)35.5 (29.5 to 49.5)0.474
    Calculated GFR (ml/min/1.73 m2) (n = 65)110.6 (88.9 to142.8)115.6 (99.2 to 153.9)100.9 (75.0 to 127.6)0.046
    Aspartate transferase (U/liter) (n = 72)37.7 (28.5 to 49.0)36.0 (25.0 to 45.7)45.0 (31.0 to 57.2)0.033
    Alanine transferase (U/liter) (n = 70)20.1 (15.0 to 33.0)19.0 (14.4 to 26.0)26.0 (16.2 to 42.5)0.076
    Alkaline phosphatase (U/liter) (n = 69)330.0 (189.0 to 529.0)331.0 (189.0 to 535.0)330.0 (149.0 to 501.0)0.486
    Total bilirubin (µmol/liter) (n = 72)5.0 (3.1 to 8.0)5.0 (3.7 to 7.0)6.5 (3.0 to 11.0)0.473
    Albumin (g/liter) (n = 70)38.5 (34.0 to 42.7)40.0 (35.0 to 42.8)36.0 (28.5 to 41.0)0.055
Median (IQR) HIV-related laboratory tests
    CD4 cell count (cells/µl) (n = 74)397.5 (169.0 to 648.0)467.0 (179.0 to 694.0)283.0 (107.0 to 588.0)0.277
    CD4 percent (%) (n = 64)14.0 (7.5 to 18.5015.0 (9.0 to 22.0)11.0 (6.0 to 18.0)0.334
    Log10 HIV-1 RNA (n = 62)5.1 (4.4 to 5.8)4.9 (4.3 to 5.4)5.7 (4.8 to 6.0)0.051
Nucleoside backbone (n = 104)b0.257
    Zidovudine + lamivudine77 (73.3)48 (77.4)29 (67.4)
    Abacavir + lamivudine27 (25.7)13 (21.0)14 (32.6)
Median (IQR) drug dosages (mg/kg)
    Isoniazid10.0 (9.0 to 11.7)
    Rifampin15.0 (13.7 to 16.8)
    Pyrazinamide25.0 (22.6 to 29.6)
    Ethambutol16.7 (15.2 to 20.0)
  • a Numbers (percent) are reported for categorical data. IQR, interquartile range; BMI, body mass index.

  • b One child received tenofovir disoproxil fumarate + lamivudine.